MAINZ-EPIREG: Mainz Epilepsy Registry

Sponsor
Johannes Gutenberg University Mainz (Other)
Overall Status
Recruiting
CT.gov ID
NCT05267405
Collaborator
(none)
700
1
72
9.7

Study Details

Study Description

Brief Summary

Prospective longitudinal observational registry study of all patients with epilepsy treated in the Mainz Comprehensive Epilepsy and Sleep Medicine Center with the focus on the course of the disease and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Other: no interventions, only observation

Detailed Description

Clinical parameters of patients, such as onset of the disease, prior medication, disease severity, which are important for the data analysis also collected retrospectively before the initiation of the registry. Data on the quality of life is collected only prospectively.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
700 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Study on Disease Course and Quality of Life in Patients With Epilepsy (Mainz Epilepsy Registry)
Actual Study Start Date :
Feb 1, 2018
Anticipated Primary Completion Date :
Jan 31, 2024
Anticipated Study Completion Date :
Jan 31, 2024

Outcome Measures

Primary Outcome Measures

  1. monthly seizure frequency after 6 months [6 months]

    monthly seizure frequency at the follow-up after 6 months

  2. European Quality of Life 5 dimensions Index (EQ 5D Index) [6 months]

    health-related quality of life measured by EQ5D-Index (European Quality of Life 5 dimensions), rating from 0 (worst possible state) to 1 (best possible state)

  3. monthly seizure frequency after 12 months [12 months]

    monthly seizure frequency at the follow-up after 12 months

  4. European Quality of Life 5 dimensions Index (EQ 5D Index) [12 months]

    health-related quality of life measured by EQ5D-Index (European Quality of Life 5 dimensions), rating from 0 (worst possible state) to 1 (best possible state)

  5. Seizure freedom [6 months]

    percentage of patients without epileptic seizures

  6. Seizure freedom [12 months]

    percentage of patients without epileptic seizures

  7. interruption of status epilepticus [48 hours]

    percentage of patients with interrupted status epilepticus

Secondary Outcome Measures

  1. Resilience Scale 13 [12 months]

    Resilience Scale 13 (short version with 13 questions): 13-66 points correspond with low resilience, 67-72 with moderate and 73-91 with high resilience

  2. Resilience Scale 13 [24 months]

    Resilience Scale 13 (short version with 13 questions): 13-66 points correspond with low resilience, 67-72 with moderate and 73-91 with high resilience

  3. Multidimensional Fatigue Inventory [12 months]

    Multidimensional Fatigue Inventory: 20-item self-report instrument designed to measure fatigue. Measures range from 0-100, representing more severe fatigue at higher scores

  4. Multidimensional Fatigue Inventory [24 months]

    Multidimensional Fatigue Inventory: 20-item self-report instrument designed to measure fatigue. Measures range from 0-100, representing more severe fatigue at higher scores

  5. Beck Depression Inventory II [12 months]

    Beck Depression Inventory II: higher scores correspond to more severe depression (range 0-63)

  6. Beck Depression Inventory II [24 months]

    Beck Depression Inventory II: higher scores correspond to more severe depression (range 0-63)

  7. Berlin Social Support Scales (BSSS) [12 months]

    Berlin Social Support Scales (BSSS) is used to assess the amount of emotional, informational and instrumental support received by patients: Total scores ranged from 15 to 60, higher scores identify better support

  8. Berlin Social Support Scales (BSSS) [24 months]

    Berlin Social Support Scales (BSSS) is used to assess the amount of emotional, informational and instrumental support received by patients: Total scores ranged from 15 to 60, higher scores identify better support

  9. World Health Organization Quality of Life-BREF (WHOQOL-BREF) [12 months]

    World Health Organization Quality of Life-BREF (WHOQOL-BREF), a scale to assess overall quality of life with a range 0-100 (higher scores correspond better quality of life)

  10. World Health Organization Quality of Life-BREF (WHOQOL-BREF) [24 months]

    World Health Organization Quality of Life-BREF (WHOQOL-BREF), a scale to assess overall quality of life with a range 0-100 (higher scores correspond better quality of life)

  11. Pittsburgh Sleep Quality Index [12 months]

    Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances, scoring between 0 and 21 with higher scores corresponding to worse sleep quality

  12. Pittsburgh Sleep Quality Index [24 months]

    Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances, scoring between 0 and 21 with higher scores corresponding to worse sleep quality

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Epileptic or psychogenic seizures
Exclusion Criteria:
  • age<18

  • patients who cannot provide informed consent and don't have a legal guardian

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mainz Comprehensive Epilepsy and Sleep Medicine Center Mainz Rheinland-Pfalz Germany 55131

Sponsors and Collaborators

  • Johannes Gutenberg University Mainz

Investigators

  • Principal Investigator: Yaroslav Winter, MD, MSc, Mainz Comprehensive Epilepsy and Sleep Medicine Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Yaroslav Winter, Head of Mainz Comprehensive Epilepsy and Sleep Medicine Center, Johannes Gutenberg University Mainz
ClinicalTrials.gov Identifier:
NCT05267405
Other Study ID Numbers:
  • MAINZ-EPIREG
First Posted:
Mar 4, 2022
Last Update Posted:
Mar 4, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 4, 2022